Apellis Pharmaceuticals, Inc. Balance Sheet
APLS / Health Care|11 years of annual SEC 10-K data (FY2015-FY2025)
Shows total assets, cash and equivalents, receivables, property and equipment, total debt, and shareholders' equity across 11 fiscal years. All figures from audited SEC 10-K filings.
Apellis Pharmaceuticals, Inc. had $1.1B in total assets and $370M in shareholders' equity as of FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -0.60 (distress zone, below 1.8 threshold)
- Negative profit margin: -25.3%
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $466.2M | $411.3M | $351.2M | $551.8M | $640.2M | $565.8M | $352.0M | $176.3M | $175.6M | $24.9M | $36.0M |
| Accounts Receivable | $366.2M | $264.9M | $206.4M | $7.7M | $10.1M | - | - | - | - | - | - |
| Inventory | $142.6M | $81.4M | $146.4M | $85.7M | $16.3M | $0 | - | - | - | - | - |
| Current Assets | $1.0B | $789.0M | $766.3M | $719.5M | $824.0M | $917.2M | $373.1M | $202.4M | $182.0M | $27.4M | - |
| PP&E (Net) | $1.7M | $3.0M | $4.3M | $6.1M | $6.2M | $6.8M | $1.7M | $977.9K | - | - | - |
| Total Assets | $1.1B | $885.1M | $788.7M | $760.2M | $881.8M | $960.6M | $389.2M | $203.5M | $182.1M | $27.4M | - |
| Current Liabilities | $323.6M | $185.5M | $247.6M | $167.6M | $131.8M | $128.3M | $65.8M | $17.0M | $6.6M | $3.6M | - |
| Total Debt | - | - | $93.0M | $92.7M | - | - | - | - | $27.0M | - | - |
| Shareholders' Equity | $370.1M | $228.5M | $194.5M | $169.9M | $198.7M | $204.6M | $34.2M | $161.0M | $148.9M | $23.8M | $35.0M |